KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $175.0 million.

  • Bristol Myers Squibb's Current Deferred Revenue fell 2117.12% to $175.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $175.0 million, marking a year-over-year decrease of 2117.12%. This contributed to the annual value of $175.0 million for FY2025, which is 2117.12% down from last year.
  • According to the latest figures from Q4 2025, Bristol Myers Squibb's Current Deferred Revenue is $175.0 million, which was down 2117.12% from $190.0 million recorded in Q3 2025.
  • Over the past 5 years, Bristol Myers Squibb's Current Deferred Revenue peaked at $367.0 million during Q1 2021, and registered a low of $175.0 million during Q4 2025.
  • Over the past 5 years, Bristol Myers Squibb's median Current Deferred Revenue value was $289.0 million (recorded in 2022), while the average stood at $278.0 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 368.1% in 2023, then plummeted by 2117.12% in 2025.
  • Over the past 5 years, Bristol Myers Squibb's Current Deferred Revenue (Quarter) stood at $330.0 million in 2021, then dropped by 12.42% to $289.0 million in 2022, then decreased by 5.19% to $274.0 million in 2023, then fell by 18.98% to $222.0 million in 2024, then dropped by 21.17% to $175.0 million in 2025.
  • Its Current Deferred Revenue was $175.0 million in Q4 2025, compared to $190.0 million in Q3 2025 and $203.0 million in Q2 2025.